Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.47 |
| ▸ | ACSS2 | Q9NR19 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249330 | 0.90 | DGAT1 (0.56) | DGAT1ACSS2MAPTSMN1; SMN2RAB9A | |
| SCHEMBL1251403 | 0.88 | DGAT1 (0.51) | DGAT1MAPTSMN1; SMN2POLBRAB9A | |
| SCHEMBL1248717 | 0.87 | DGAT1 (0.48) | DGAT1ACSS2MAPTSMN1; SMN2POLB | |
| SCHEMBL3171231 | 0.82 | PTGER4 (0.48) | ACSS2MAPTPIN1 | |
| SCHEMBL1250538 | 0.81 | ACSS2 (0.49) | DGAT1ACSS2SMN1; SMN2POLBRAB9A | |
| SCHEMBL1250558 | 0.81 | MAPT (0.46) | DGAT1ACSS2MAPTSMN1; SMN2POLB | |
| SCHEMBL1249228 | 0.80 | RAB9A (0.48) | DGAT1ACSS2MAPTSMN1; SMN2PIN1 | |
| SCHEMBL1250280 | 0.76 | DGAT1 (0.61) | DGAT1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1250370 | 0.74 | DGAT1 (0.53) | DGAT1MAPTSMN1; SMN2POLBRAB9A | |
| SCHEMBL3167934 | 0.72 | PTGER4 (0.49) | ACSS2PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046133-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885ACSS2 128/4885MAPT 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.